The Company now expects a decrease in cash, cash equivalents, and investments of approximately $230M in 2023. Based on current expectation, the Company expects its cash runway to be sufficient to fund operations into Q2 2025. GAAP Operating Expenses are expected to be approximately $340M including estimated non-cash stock-based compensation expense of approximately $80M. These estimates exclude any impact from potential business development activities.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ALLO:
- Allogene Therapeutics Reports First Quarter 2023 Financial Results and Business Update
- Allogene Therapeutics Announces Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting
- Allogene to present Phase 1 Data from ALLO-501/501A trials at ASCO
- Allogene Therapeutics Appoints Timothy Moore as Chief Technical Officer
- Allogene Therapeutics appoints Timothy Moore as chief technical officer
